Dr. Wierda on Ibrutinib Plus Venetoclax in CLL
February 22nd 2017William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses a clinical trial exploring the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) in patients with chronic lymphocytic leukemia (CLL).
Dr. Neelapu on ZUMA-1 Trial Design of KTE-C19
February 17th 2017Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the design of the ZUMA-1 trial of the chimeric antigen receptor (CAR) T-cell therapy KTE-C19 for patients with aggressive lymphomas.
Rozita Yarmand on Tumor Suppressor Gene in Medullary Thyroid Cancer
February 15th 2017Rozita Yarmand, PhD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders-Research, The University of Texas MD Anderson Cancer Center, discusses how ATF4 targets RET for degradation and is a candidate tumor suppressor gene in medullary thyroid cancer.
Dr. Barcenas on Colestipol in Management of Neratinib Side Effects in HER2+ Breast Cancer
February 14th 2017Carlos Barcenas, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses managing neratinib-related side effects with colestipol (Colestid).
Dr. Barcenas on Neratinib-Related Diarrhea in HER2+ Breast Cancer
February 4th 2017Carlos Barcenas, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, discusses side effects of neratinib in patients with HER2-positive early-stage breast cancer.
Trial Explores Eliminating Breast Cancer Surgery in Exceptional Responders to Neoadjuvant Therapy
February 2nd 2017Henry M. Kuerer, MD, PhD, discusses surgical advancements in the field of breast cancer and the goals of a phase II single-center trial and how it could impact these exceptional responders.
Dr. Neelapu on Next Steps With KTE-C19 in Lymphoma
February 2nd 2017Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the next steps with KTE-C19, an anti-CD19 chimeric antigen receptor T-cell therapy explored in the ZUMA-1 trial for patients with aggressive lymphomas.
Dr. Klopp on Data Comparing Standard Radiation With IMRT in Gynecologic Malignancies
January 31st 2017Ann H. Klopp, MD, PhD, an associate professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center, discusses data from a trial comparing standard radiation therapy with intensity-modulated radiation therapy in patients with gynecologic malignancies.
Dr. Lin on Advances in Radiation Therapy for Esophageal Cancer
January 28th 2017Steven H. Lin, MD, PhD, associate professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses advances in radiation therapy for patients with esophageal cancer.
Dr. Tereffe on Treatment After Neoadjuvant Chemotherapy in Breast Cancer
January 24th 2017Welela Tereffe, MD, associate professor, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses the role of radiation therapy in the treatment of patients with breast cancer who previously received neoadjuvant chemotherapy.
Dr. Dadu on Immunotherapy in Thyroid Cancer
January 14th 2017Ramona Dadu, MD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of immunotherapy to treat patients with thyroid cancer.
Dr. Neelapu on the Safety Profile of KTE-C19 in Patients With Lymphoma
January 12th 2017Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety profile of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy explored in the ZUMA-1 trial for patients with aggressive lymphomas.
Dr. Mittendorf on Vaccines as Prevention for Breast Cancer
January 6th 2017Elizabeth A. Mittendorf, MD, PhD, associate professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center, discusses the possibility of using vaccines as a preventative measure for breast cancer, particularly to fight recurrence.
Dr. Dadu on Treatment Approaches in Medullary Thyroid Cancer
December 22nd 2016Ramona Dadu, MD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment approaches in medullary thyroid cancer.
Dr. Klopp on Goals With IMRT in Gynecological Cancers
December 20th 2016Ann H. Klopp, MD, PhD, an associate professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center, discusses the next steps to take with pelvic intensity-modulated radiation therapy for patients with gynecological cancers.
Dr. Klopp on a Comparison of Standard Radiation to IMRT in Gynecologic Malignancies
December 14th 2016Ann H. Klopp, MD, PhD, an associate professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center, discusses the results of a study that compared the respective toxicities and quality of life outcomes associated with standard radiation and pelvic intensity-modulated radiation therapy for patients with various gynecologic malignancies.
Dr. Kantarjian on Future Role of Chemotherapy in Patients With ALL
December 3rd 2016Hagop M. Kantarjian, MD, professor, department of Leukemia, division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the evolving and future role of chemotherapy in the treatment paradigm of acute lymphoblastic leukemia (ALL).
Dr. Duvic on Importance of Classifying T-Cell Lymphomas
November 4th 2016Madeleine Duvic, MD, professor of Medicine and Dermatology, Blanche Bender Professorship in Cancer Research, director of the Research Fellowship Program, Department of Dermatology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of classifying T-cell lymphomas and new targets in development. Duvic shared this insight during the 2016 OncLive State of the Science Summit on Hematologic Malignancies.
Speed Critical With Anaplastic Thyroid Cancer Diagnosis, Treatment
November 3rd 2016Enrolling clinical trials can be a long process, especially in rare diseases with limited patient populations. This is a particularly significant issue for patients with anaplastic thyroid cancer, an extremely rare and aggressive disease.
Dr. Garcia-Manero on Curing Patients With MDS and AML
November 2nd 2016Guillermo Garcia-Manero, MD, professor of Medicine, chief, Section of Myelodysplastic Syndromes, in the Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the potential of curing patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Garcia-Manero explained this reasoning in an interview during the 2016 OncLive State of the Science Summit on Treatment of Hematologic Malignancies.
Practitioner Predicts Promising Future for MDS, AML Care
November 2nd 2016When envisioning the future treatment paradigms for myelodysplastic syndromes and acute myeloid leukemia, researchers predict that hypomethylating agents, immunotherapies, and multikinase and BCL-2 inhibitors are just a few examples of what the field can expect in the coming years.